Latest news and updates and the global coronavirus pandemic.
Johnson & Johnson could produce 1 billion doses of its potential COVID-19 vaccine next year if it proves successful and would consider injecting healthy volunteers with the novel coronavirus if there are not enough patients for final trials, a company executive said. J&J kicked off in July early-stage human safety trials for its potential COVID-19 vaccine after releasing details of a study in monkeys that showed its best-performing candidate offered strong protection in a single dose. Large-scale trials are set to start by the beginning of October and J&J aims to have results on the vaccine's efficacy between the end of this year and mid-2021, Johan Van Hoof, head of vaccines at Janssen, told Reuters on Tuesday in a telephone interview.
New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.